These results may imply a counterbalancing increase of FGF-21, when NAFLD progresses to advanced disease, thus possibly supporting the ongoing clinical trials of FGF-21 analogs in patients with NASH. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.